Figure 4 | Scientific Reports

Figure 4

From: SomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH)

Figure 4

Identification of SomaScan analytes (serum proteins) significantly correlated to baseline clinical measures. (a) Venn diagram showing common analytes correlated to liver fat assessed using MRI-PDFF, ALT and AST; (b) KEGG pathway analyses of common analytes from (a); (c) Venn diagram comparing baseline correlated analytes with those changing with clesacostat treatment; (d) KEGG pathway analyses of analytes correlated at baseline as well as changing with clesacostat treatment. (Spearman's correlation with adjusted p-value cutoff of < 0.05 for baseline correlation and unadjusted p-value cutoff of < 0.05 for treatment response).

Back to article page